Generating Reliable Real-World Evidence for GLP-1 Drugs

Introduction

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the treatment of obesity and type 2 diabetes. Consequently, their use has surged in recent years. While clinical trials show high efficacy, many questions remain about their optimal use in everyday practice. Fortunately, clinical researchers are increasingly utilizing real-world evidence to address these critical gaps.

The Challenges of Real-World Evidence

Currently, electronic health records, insurance claims, and clinical registries serve as primary data sources. However, relying on these sources presents significant challenges. For example, researchers often encounter poor data quality and selection bias. Furthermore, incomplete records make it difficult to track exact medication adherence and health outcomes. Therefore, experts must develop standardized methods to ensure the validity of the resulting evidence.

Innovative Strategies for Real-World Evidence

To overcome these obstacles, researchers are exploring advanced clinical methodologies. Specifically, presenters at a recent National Institute of Diabetes and Digestive and Kidney Diseases workshop highlighted pragmatic clinical trials. Additionally, they recommended target trial emulation as a key strategy. This approach simulates a randomized trial using observational data. Consequently, this design helps researchers establish causal relationships while minimizing common biases. Ultimately, these strategies will provide clinicians with more reliable data to guide patient care.

Why This Matters for Indian Clinicians

In India, the use of GLP-1 receptor agonists is growing rapidly due to the high burden of type 2 diabetes and obesity. However, local clinical guidelines often rely on Western clinical trials. Therefore, generating local, high-quality real-world data is essential. This information will help Indian physicians understand how these medications perform in diverse real-world settings. Furthermore, it will support policymakers in making informed healthcare coverage decisions.

Frequently Asked Questions

Q1: What are the main challenges when using real-world data for GLP-1 therapies?

The primary challenges include poor data quality, selection bias, and incomplete tracking of medication adherence.

Q2: How can researchers improve the validity of real-world evidence?

Specifically, researchers can use pragmatic clinical trials and target trial emulation to improve study design and strengthen causal inference.

Q3: Why did the NIDDK convene this workshop?

Consequently, the workshop brought together experts to discuss the limitations of real-world data and find methodological solutions.

References

1. Curtis LH et al. Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. Ann Intern Med. 2026 Jun 30. doi: 10.7326/ANNALS-26-00202. PMID: 42372277.
2. Arterburn D et al. Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. Ann Intern Med. 2026 Jun 30. doi: 10.7326/ANNALS-25-05468.